XomaXOMA
XOMA
About: XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
Employees: 13
0
Funds holding %
of 7,290 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
57% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 14
1% more capital invested
Capital invested by funds: $203M [Q3] → $205M (+$1.55M) [Q4]
0.55% more ownership
Funds ownership: 65.78% [Q3] → 66.33% (+0.55%) [Q4]
3% less funds holding
Funds holding: 67 [Q3] → 65 (-2) [Q4]
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
33% less funds holding in top 10
Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]
53% less call options, than puts
Call options by funds: $32K | Put options by funds: $68K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$104
384%
upside
Avg. target
$104
384%
upside
High target
$104
384%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 23% 1-year accuracy 93 / 410 met price target | 384%upside $104 | Buy Maintained | 3 Feb 2025 |
Financial journalist opinion
Based on 3 articles about XOMA published over the past 30 days
Neutral
GlobeNewsWire
6 days ago
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences
Capital will fund Castle Creek's D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors invested $25 million in return for a high-single digit royalty on D-Fi JUPITER, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has closed a royalty financing agreement with Castle Creek Biosciences, Inc. to support the Phase 3 clinical study of D-Fi (FCX-007), Castle Creek's lead candidate, in patients with dystrophic epidermolysis bullosa (DEB).
Neutral
GlobeNewsWire
1 week ago
XOMA Royalty to Present at Investor Conferences in March
EMERYVILLE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following investor conferences in March. Management will also participate in one-on-one investor meetings.
Neutral
GlobeNewsWire
3 weeks ago
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
EMERYVILLE, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtually, February 11-12, 2025.
Neutral
GlobeNewsWire
2 months ago
XOMA Royalty Declares Quarterly Preferred Stock Dividends
EMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share.
Positive
Zacks Investment Research
3 months ago
What Makes XOMA Royalty (XOMA) a New Buy Stock
XOMA Royalty (XOMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Negative
Zacks Investment Research
3 months ago
XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates
XOMA Royalty (XOMA) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.60 per share a year ago.
Neutral
GlobeNewsWire
3 months ago
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
Zevra's MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty's portfolio
Neutral
Business Wire
4 months ago
Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has entered into a royalty purchase agreement with XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator. Under the terms of the agreement, XOMA Royalty will provide Twist Bioscience an upfront payment of $15 million in cash in exchange for the right t.
Neutral
GlobeNewsWire
4 months ago
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
XOMA Royalty has acquired 50 percent of Twist's existing royalty and milestone economics for $15 million XOMA Royalty's portfolio now holds over 100 assets ranging from revenue-generating commercial therapeutics to pre-clinical programs EMERYVILLE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) announced today it has entered into a $15 million royalty monetization arrangement with Twist Bioscience Corporation to acquire a 50 percent economic interest in all future milestones and royalties associated with the 60-plus partnered early-stage programs across 30 partners enabled by Twist Bioscience's Biopharma Solutions business unit.
Positive
Seeking Alpha
4 months ago
XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties
XOMA Royalty Corporation offers diversified revenue streams from milestone and royalty rights in various therapeutic areas, providing stable returns with lower clinical trial risks. The company's preferred shares, XOMAP and XOMAO, offer high, reliable dividends, making them attractive for income investors seeking biotech exposure. XOMA's robust financials, including substantial cash reserves and non-dilutive financing, ensure the sustainability of dividend payments for many years.
Charts implemented using Lightweight Charts™